VA Resuming use of Janssen COVID-19 Vaccine
VA will resume offering the Johnson & Johnson (Janssen) COVID-19 vaccine to individuals 18 years and older, in accordance with Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) guidance, following a 10-day pause recommended by the CDC and FDA after a very small number of people who received the vaccine experienced rare but serious blood clots. After careful review and evaluation, the FDA and CDC have confidence that this vaccine is safe for use and effective in preventing COVID-19. The available data show that the vaccine’s benefits outweigh its risks and the chance of blood clots occurring following its administration is very low.
Anyone who is offered the J&J vaccine from VA will receive information about the potential risks and benefits of the vaccine, including the rare risk of blood clots and will be made aware of alternative vaccine options. The primary goal of COVID-19 vaccination is to protect those we serve from COVID-19, and VA’s priority remains the safety of all those receiving vaccine from VA, including Veterans, their spouses, caregivers, employees and federal partners.
The FDA letter granting amendment to the EUA is here: Janssen Letter Granting EUA Amendment (April 23, 2021) (fda.gov). Health care providers administering the vaccine and vaccine recipients or caregivers should review the Janssen COVID-19 Vaccine Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Fact Sheet for Recipients and Caregivers, which have been revised to include information about the risk of this syndrome and has occurred in a very small number of people who have received the Janssen COVID-19 Vaccine.
Questions can be submitted to the COVID-19 Resource Room via email to VHACOVIDRR@va.gov.